InsidersTradesSigma
Total declarations
Companies
▲ Purchases (8 ops.)
▼ Sales (2 ops.)
Discover the complete record of transactions filed by CONWAY ROBERT E, Director. Director active across 3 companies, notably ARCA biopharma, Inc.. Cumulatively, 10 filings have been logged. Total volume traded: €762k. The latest transaction was disclosed on 23 September 2021 — Acquisition. Regulator: SEC (Form 4). The full history is openly available.
Declarations10 total
€128,74815,000 shares@ €8.583237.7% of flow
Common Stock
SEC:0001626199-21-000130·
Ideal exit: 20 Jun 2022 (T+270)
€128,74815,000 shares@ €8.583218.9% of flow
Common Stock
SEC:0001626199-21-000130:0·
Ideal exit: 20 Jun 2022 (T+270)
€128,74815,000 shares@ €8.583237.7% of flow
Common Stock
SEC:0001626199-21-000127·
€128,74815,000 shares@ €8.583218.9% of flow
Common Stock
SEC:0001626199-21-000127:0·
€83,56810,000 shares@ €8.356824.5% of flow
Common Stock
SEC:0001626199-21-000120·
Ideal exit: 18 Jun 2022 (T+270)
€83,56810,000 shares@ €8.356812.3% of flow
Common Stock
SEC:0001626199-21-000120:0·
Ideal exit: 18 Jun 2022 (T+270)
€26,44910,000 shares@ €2.6449100.0% of flow
Common Stock
SEC:0001209191-21-032381·
Ideal exit: 6 Feb 2022 (T+270)
€26,44910,000 shares@ €2.644933.1% of flow
Common Stock
SEC:0001209191-21-032381:0·
Ideal exit: 6 Feb 2022 (T+270)
10,000 shares
Common Stock
SEC:0001209191-21-030629·
Ideal exit: 30 Jan 2022 (T+270)
€26,93610,000 shares@ €2.693633.7% of flow
Common Stock
SEC:0001209191-21-030629:0·
Ideal exit: 30 Jan 2022 (T+270)
10 of 10 declarations
About CONWAY ROBERT E
Robert E. Conway is a Director of ARCA biopharma, Inc. and ALPINE IMMUNE SCIENCES, INC. He brings extensive experience in corporate governance and strategic decision-making. His role involves overseeing the company's activities and ensuring that shareholder interests are safeguarded. His contribution is essential in guiding these companies within the biopharmaceutical sector.
